Most likely as they are located in Australia where stem cell are more excepted at Mike Tomas said. Plus they have the backing of TEVA. They are a large generic pharma company. Since Mesoblast is a generic allogeneic stem cell company, they are a good fit for TEVA. The problem for them is autologous stem cells have been shown to be safer and more effective in studies which is what Bioheart uses.
News 
Market Data 
Discover 
AI
